Three Decades of Ultrasound Contrast Agents: A Review of the Past, Present and Future Improvements

Peter Frinking*, Tim Segers, Ying Luan, François Tranquart

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Initial reports from the 1960s describing the observations of ultrasound contrast enhancement by tiny gaseous bubbles during echocardiographic examinations prompted the development of the first ultrasound contrast agent in the 1980s. Current commercial contrast agents for echography, such as Definity, Optison, Sonazoid and SonoVue, have proven to be successful in a variety of on- and off-label clinical indications. Whereas contrast-specific technology has seen dramatic progress after the introduction of the first approved agents in the 1990s, successful clinical translation of new developments has been limited during the same period, while understanding of microbubble physical, chemical and biologic behavior has improved substantially. It is expected that for a successful development of future opportunities, such as ultrasound molecular imaging and therapeutic applications using microbubbles, new creative developments in microbubble engineering and production dedicated to further optimizing microbubble performance are required, and that they cannot rely on bubble technology developed more than 3 decades ago.

Original languageEnglish
JournalUltrasound in medicine and biology
Early online date13 Jan 2020
DOIs
Publication statusE-pub ahead of print/First online - 13 Jan 2020

Fingerprint

Microbubbles
Contrast Media
Ultrasonography
bubbles
Technology
Molecular Imaging
indication
examination
engineering
augmentation
Therapeutics

Keywords

  • Contrast agents
  • Definity
  • Microbubbles
  • Monodisperse
  • Optison
  • Sonazoid
  • SonoVue
  • Ultrasound

Cite this

@article{12c72d9cb7024ae58b779457e30bad24,
title = "Three Decades of Ultrasound Contrast Agents: A Review of the Past, Present and Future Improvements",
abstract = "Initial reports from the 1960s describing the observations of ultrasound contrast enhancement by tiny gaseous bubbles during echocardiographic examinations prompted the development of the first ultrasound contrast agent in the 1980s. Current commercial contrast agents for echography, such as Definity, Optison, Sonazoid and SonoVue, have proven to be successful in a variety of on- and off-label clinical indications. Whereas contrast-specific technology has seen dramatic progress after the introduction of the first approved agents in the 1990s, successful clinical translation of new developments has been limited during the same period, while understanding of microbubble physical, chemical and biologic behavior has improved substantially. It is expected that for a successful development of future opportunities, such as ultrasound molecular imaging and therapeutic applications using microbubbles, new creative developments in microbubble engineering and production dedicated to further optimizing microbubble performance are required, and that they cannot rely on bubble technology developed more than 3 decades ago.",
keywords = "Contrast agents, Definity, Microbubbles, Monodisperse, Optison, Sonazoid, SonoVue, Ultrasound",
author = "Peter Frinking and Tim Segers and Ying Luan and Fran{\cc}ois Tranquart",
year = "2020",
month = "1",
day = "13",
doi = "10.1016/j.ultrasmedbio.2019.12.008",
language = "English",
journal = "Ultrasound in medicine and biology",
issn = "0301-5629",
publisher = "Elsevier",

}

Three Decades of Ultrasound Contrast Agents : A Review of the Past, Present and Future Improvements. / Frinking, Peter; Segers, Tim; Luan, Ying; Tranquart, François.

In: Ultrasound in medicine and biology, 13.01.2020.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Three Decades of Ultrasound Contrast Agents

T2 - A Review of the Past, Present and Future Improvements

AU - Frinking, Peter

AU - Segers, Tim

AU - Luan, Ying

AU - Tranquart, François

PY - 2020/1/13

Y1 - 2020/1/13

N2 - Initial reports from the 1960s describing the observations of ultrasound contrast enhancement by tiny gaseous bubbles during echocardiographic examinations prompted the development of the first ultrasound contrast agent in the 1980s. Current commercial contrast agents for echography, such as Definity, Optison, Sonazoid and SonoVue, have proven to be successful in a variety of on- and off-label clinical indications. Whereas contrast-specific technology has seen dramatic progress after the introduction of the first approved agents in the 1990s, successful clinical translation of new developments has been limited during the same period, while understanding of microbubble physical, chemical and biologic behavior has improved substantially. It is expected that for a successful development of future opportunities, such as ultrasound molecular imaging and therapeutic applications using microbubbles, new creative developments in microbubble engineering and production dedicated to further optimizing microbubble performance are required, and that they cannot rely on bubble technology developed more than 3 decades ago.

AB - Initial reports from the 1960s describing the observations of ultrasound contrast enhancement by tiny gaseous bubbles during echocardiographic examinations prompted the development of the first ultrasound contrast agent in the 1980s. Current commercial contrast agents for echography, such as Definity, Optison, Sonazoid and SonoVue, have proven to be successful in a variety of on- and off-label clinical indications. Whereas contrast-specific technology has seen dramatic progress after the introduction of the first approved agents in the 1990s, successful clinical translation of new developments has been limited during the same period, while understanding of microbubble physical, chemical and biologic behavior has improved substantially. It is expected that for a successful development of future opportunities, such as ultrasound molecular imaging and therapeutic applications using microbubbles, new creative developments in microbubble engineering and production dedicated to further optimizing microbubble performance are required, and that they cannot rely on bubble technology developed more than 3 decades ago.

KW - Contrast agents

KW - Definity

KW - Microbubbles

KW - Monodisperse

KW - Optison

KW - Sonazoid

KW - SonoVue

KW - Ultrasound

UR - http://www.scopus.com/inward/record.url?scp=85077753763&partnerID=8YFLogxK

U2 - 10.1016/j.ultrasmedbio.2019.12.008

DO - 10.1016/j.ultrasmedbio.2019.12.008

M3 - Review article

AN - SCOPUS:85077753763

JO - Ultrasound in medicine and biology

JF - Ultrasound in medicine and biology

SN - 0301-5629

ER -